Ningbo Haichuan Yongxni Pharmaceutical Technology Co., Ltd. is a comprehensive biopharmaceutical company, which is mainly engaged in the research and development of related compounds in the development of new drugs and specialty pharmaceutical raw materials, the research and development of advanced intermediates, organic synthetic blocks, and the research and sales of high-end reagents. At the same time, the company also provides domestic and foreign pharmaceutical enterprises with new drug and generic drug development, drug license application, production technology improvement services.

The company follows the standard modern enterprise management system, has established the scientific decision, the reasonable division of labor, the communication smooth, the responsibility clear organization structure, according to the management actual need, the company will technology, the product research and development, the quality, the market and the logistics carries on the scientific organic union.

The company has a technology research and development center and a number of production bases, among which the total construction area of the research and development laboratory is about 20,000 square meters, with a fully functional research and development platform, covering organic synthesis, biological fermentation, pharmaceutical analysis, biological analysis and other fields of the pharmaceutical industry. The company has a scientific system of drug research and development and quality assurance system, equipped with international advanced process equipment and analytical instruments, set up the develop from small to pilot enlarge API process, quality and stability research platform, covering the whole process of drug development, specification to carry out innovation drugs and generic drugs research and development and quality consistency evaluation of the project. The production base is mainly distributed in Shanxi and Gansu, covering an area of about 400 mu, and is equipped with more than 200 reactors of various types, with reaction volumes ranging from 200 to 10000L.

The company's existing equipment and other hardware conditions are fully capable of meeting the industrialization of the production needs of each project. The company focuses on the introduction and training of professional and technical personnel, has a nearly 100 technical research and development personnel composed of the core technology development team, specializing in biomedical chemical products technology research, development and design. The average core team members have more than 10 years of industry research and development experience, and all have bachelor's degree or above, among which doctoral degree and master's degree account for 20%.

The company focuses on innovative medicine key technology research and development and industrialization to create a domestic and world leading, become a national pharmaceutical technology innovation service enterprises.